Thymic tumors: radiotherapy experience for single institute.

IF 2.7 3区医学 Q3 ONCOLOGY

Strahlentherapie und Onkologie Pub Date : 2025-04-23 DOI:10.1007/s00066-025-02395-y

Sureyya Sarihan, Aybuke Tugce Metin, Ahmet Sami Bayram, Huseyin Melek

{"title":"Thymic tumors: radiotherapy experience for single institute.","authors":"Sureyya Sarihan, Aybuke Tugce Metin, Ahmet Sami Bayram, Huseyin Melek","doi":"10.1007/s00066-025-02395-y","DOIUrl":null,"url":null,"abstract":"Purpose: The aim is to evaluate treatment outcomes and prognostic factors in patients with thymic epithelial tumor (TET) treated with radiotherapy (RT).Methods: Sixty-four patients were treated between 2000 and 2023. The median age was 52 years (20-83), and 81% of underwent R0 resection. The stage (s) distribution for I, II, III, and IV were 5%, 61%, 26%, and 8% by Masaoka-Koga and 63%, 11%, 17%, and 9% by TNM, respectively. WHO types A/AB/B/C and thymic neuroendocrine tumors were seen in 5%, 22%, 64%, 6%, and 3% of patients, respectively. The median RT dose was 5040 cGy (1620-6596). Survival was calculated from the beginning of RT.Results: The median follow-up was 70 months (1.5-268). The median time to recurrence was 30 months (6.5-106), seen in 23% of patients. Mean overall (OS), progression-free survival (PFS) and 5‑year local control were 141, 138 months, and 82.4%, respectively. In univariate analysis, the presence of organ invasion and TNM stage were significant as new prognostic factors for survival (p < 0.05). In multivariate analysis, the high-risk group (B2/B3/C) and another surgical center (p < 0.05) for OS, and KPS ≤ 80, thymic carcinoma, and Masaoka-Koga sIII-IV (p < 0.05) for PFS were identified as unfavorable prognostic factors.Conclusion: Recurrence in TET can occur over a longer period. In this study, 5‑year local control of 82.4% was achieved. The prognostic importance of KPS, histology, Masaoka-Koga stage, risk group, and surgical center was demonstrated. Advances in the diagnosis, staging, and treatment of TET will enable more personalized treatment.","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-025-02395-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim is to evaluate treatment outcomes and prognostic factors in patients with thymic epithelial tumor (TET) treated with radiotherapy (RT).

Methods: Sixty-four patients were treated between 2000 and 2023. The median age was 52 years (20-83), and 81% of underwent R0 resection. The stage (s) distribution for I, II, III, and IV were 5%, 61%, 26%, and 8% by Masaoka-Koga and 63%, 11%, 17%, and 9% by TNM, respectively. WHO types A/AB/B/C and thymic neuroendocrine tumors were seen in 5%, 22%, 64%, 6%, and 3% of patients, respectively. The median RT dose was 5040 cGy (1620-6596). Survival was calculated from the beginning of RT.

Results: The median follow-up was 70 months (1.5-268). The median time to recurrence was 30 months (6.5-106), seen in 23% of patients. Mean overall (OS), progression-free survival (PFS) and 5‑year local control were 141, 138 months, and 82.4%, respectively. In univariate analysis, the presence of organ invasion and TNM stage were significant as new prognostic factors for survival (p < 0.05). In multivariate analysis, the high-risk group (B2/B3/C) and another surgical center (p < 0.05) for OS, and KPS ≤ 80, thymic carcinoma, and Masaoka-Koga sIII-IV (p < 0.05) for PFS were identified as unfavorable prognostic factors.

Conclusion: Recurrence in TET can occur over a longer period. In this study, 5‑year local control of 82.4% was achieved. The prognostic importance of KPS, histology, Masaoka-Koga stage, risk group, and surgical center was demonstrated. Advances in the diagnosis, staging, and treatment of TET will enable more personalized treatment.

查看原文本刊更多论文

胸腺肿瘤：单院放疗经验。

目的：目的是评估胸腺上皮肿瘤（TET）放疗（RT）患者的治疗效果和预后因素。方法：2000年至2023年共收治64例患者。中位年龄为52岁（20-83岁），81%的患者行R0切除术。Masaoka-Koga的I、II、III和IV阶段分布分别为5%、61%、26%和8%，TNM的阶段分布分别为63%、11%、17%和9%。WHO A/AB/B/C型和胸腺神经内分泌肿瘤分别见于5%、22%、64%、6%和3%的患者。中位放射治疗剂量为5040 cGy（1620-6596）。结果：中位随访时间为70个月（1.5-268）。23%的患者中位复发时间为30个月（6.5-106）。平均总生存期（OS）、无进展生存期（PFS）和5年局部控制期分别为141个月、138个月和82.4%。在单因素分析中，器官侵犯的存在和TNM分期是影响生存的重要新预后因素（p ）结论：TET复发可在较长时间内发生。本研究5年局部控制率为82.4%。证实KPS、组织学、正冈-古贺氏分期、危险组和手术中心对预后的重要性。TET的诊断、分期和治疗方面的进步将使治疗更加个性化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Strahlentherapie und Onkologie 医学-核医学

CiteScore

5.70

自引率

12.90%

发文量

141

审稿时长

3-8 weeks

期刊介绍： Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.